The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.

被引：0
|
作者：
Kong, SY [1 ]
Kwon, Y [1 ]
Lee, DH [1 ]
Lee, JS [1 ]
Lee, ES [1 ]
Ro, J [1 ]
机构：
[1] Natl Canc Ctr, Goyang, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：48S / 48S
页数：1
相关论文
共 50 条
  • [41] In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer
    Melanie Spears
    Karen J. Taylor
    Alison F. Munro
    Carrie A. Cunningham
    Elizabeth A. Mallon
    Chris J. Twelves
    David A. Cameron
    Jeremy Thomas
    John M. S. Bartlett
    Breast Cancer Research and Treatment, 2012, 132 : 463 - 470
  • [42] Chromogenic in-situ hybridization:: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm
    Hanna, WM
    Kwok, K
    MODERN PATHOLOGY, 2006, 19 (04) : 481 - 487
  • [43] Chromogenic in situ hybridization (CISH) study of HER2 and Topo2α amplifications in metastatic breast cancer
    Todorovic-Rakovic, N.
    Neskovic-Konstantinovic, Z.
    Nikolic-Vukosavljevic, D.
    CHROMOSOME RESEARCH, 2009, 17 : 95 - 96
  • [44] Early results of combined Her-2/neu (HER2) immunotherapy using a HER2 peptide vaccine with concurrent trastuzumab for metastatic breast cancer.
    Webster, D.
    Waisman, J.
    MacLeod, B.
    dela Rosa, C.
    Higgins, D.
    Fintak, P.
    Childs, J.
    Slota, M.
    Salazar, L.
    Disis, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S79 - S80
  • [45] Her2 amplification - Correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization
    Wixom, CR
    Albers, EA
    Weidner, N
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2004, 12 (03) : 248 - 251
  • [46] The comparison of HER2 low and HER2 0 in ductal carcinoma in situ (DCIS) for breast cancer
    Kureyama, Nari
    Kusudo, Maho
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Nozawa, Kazuki
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
  • [47] HER2 testing in metastatic breast cancer - is reflex in situ hybridization necessary in cases that are equivocal by immunohistochemistry?
    Liwski, C. R.
    Castonguay, M.
    Barnes, P.
    Bethune, G.
    Rayson, D.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2021, 156 : S27 - S28
  • [48] Quantitative Imaging Analysis Fluorescence In Situ Hybridization Validation for Clinical HER2 Testing in Breast Cancer
    Wilcock, Diane M.
    Moore, Kristina H.
    Rowe, Leslie
    Mahlow, Jonathan
    Jedrzkiewicz, Jolanta
    Cleary, Allison S.
    Lomo, Lesley
    Ruano, Ana L.
    Gering, Maarika
    Bradshaw, Derek
    Maughan, Meghan
    Tran, Phuong
    Burlingame, Jesse
    Davis, Richard
    Affolter, Kajsa
    Albertson, Daniel J.
    Adelhardt, Parisa
    Kim, Jong Take
    Coleman, Joshua F.
    Deftereos, Georgios
    Gulbahce, Evin H.
    Sirohi, Deepika
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2023, 147 (12) : 1402 - 1412
  • [49] Clinicopathologic features and prognosis of breast cancer with low HER2 expression evaluated by fluorescence in situ hybridization
    Sato, Ayana
    Naruse, Saki
    Isono, Yuka
    Maeda, Yuka
    Yamada, Miki
    Matsumoto, Akiko
    Ikeda, Tatsuhiko
    Jinno, Hiromitsu
    CANCER RESEARCH, 2024, 84 (09)
  • [50] Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization:: a technical review with interpretive guidelines
    Hicks, DG
    Tubbs, RR
    HUMAN PATHOLOGY, 2005, 36 (03) : 250 - 261
12345